Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 6/20 | 0.42 |
| ▸ | RORC | P51449 | 2/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12437852 | 0.90 | UTS2R (0.44) | UTS2RTP53THRBLMNA | |
| SCHEMBL12437886 | 0.90 | UTS2R (0.46) | UTS2RRORCSLC6A5OPRM1OPRD1 | |
| SCHEMBL12437875 | 0.89 | UTS2R (0.45) | UTS2RRORCTP53THRBLMNA | |
| SCHEMBL12437856 | 0.85 | UTS2R (0.46) | UTS2RTP53THRBLMNA | |
| SCHEMBL12437892 | 0.83 | MCHR2 (0.42) | UTS2RRORCTP53THRBLMNA | |
| SCHEMBL12437873 | 0.83 | UTS2R (0.47) | UTS2RSLC6A5OPRM1OPRD1TP53 | |
| SCHEMBL12437896 | 0.82 | UTS2R (0.44) | UTS2RRORCSLC6A5OPRM1OPRD1 | |
| SCHEMBL12437904 | 0.81 | UTS2R (0.43) | UTS2RRORCTP53THRBLMNA | |
| SCHEMBL12437851 | 0.80 | UTS2R (0.44) | UTS2RTP53 | |
| SCHEMBL12437913 | 0.80 | UTS2R (0.48) | UTS2RSLC6A5OPRM1OPRD1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | HPGDS, HPGD, DPYD | UTS2R 854/4885RORC 1725/4885SLC6A5 4085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.